Trazodone
Trazodone (trazodone) is a small molecule pharmaceutical. Trazodone was first approved as Desyrel on 1982-01-01. It is used to treat depressive disorder and sleep initiation and maintenance disorders in the USA. The pharmaceutical is active against 5-hydroxytryptamine receptor 2C and 5-hydroxytryptamine receptor 2A. In addition, it is known to target 5-hydroxytryptamine receptor 2B.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
| mental disorders | D001523 |
Trade Name
FDA
EMA
Trazodone (discontinued: Desyrel, Oleptro, Trazodone)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Trazodone hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| OLEPTRO | Angelini Pharma | N-022411 DISCN | 2010-02-02 | 2 products, RLD |
| DESYREL | Pragma Pharmaceuticals | N-018207 DISCN | 1982-01-01 | 4 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| desyrel | ANDA | 2010-01-22 |
| trazamine | unapproved drug other | 2011-08-01 |
| trazodone hcl | ANDA | 2024-08-16 |
| trazodone hydrochloride | ANDA | 2024-11-01 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| sleep initiation and maintenance disorders | — | D007319 | F51.01 |
| depressive disorder | EFO_1002014 | D003866 | F32.A |
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
69 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Depression | D003863 | — | F33.9 | 4 | 3 | 4 | 2 | 6 | 18 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | 2 | 3 | 4 | 2 | 4 | 14 |
| Sleep initiation and maintenance disorders | D007319 | — | F51.01 | 1 | — | 3 | 2 | 3 | 9 |
| Sleep apnea syndromes | D012891 | HP_0010535 | G47.3 | 3 | 2 | — | 4 | 1 | 9 |
| Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | 4 | 2 | — | 3 | 1 | 8 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 1 | 2 | 2 | 2 | 7 |
| Apnea | D001049 | HP_0002104 | R06.81 | 1 | — | — | 3 | 1 | 5 |
| Sleep wake disorders | D012893 | — | G47 | — | 1 | 2 | 1 | — | 4 |
| Treatment-resistant depressive disorder | D061218 | — | — | — | — | 1 | 1 | 1 | 3 |
| Wounds and injuries | D014947 | — | T14.8 | 1 | — | — | 1 | 1 | 3 |
Show 16 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | 1 | 2 | — | — | 3 |
| Parasomnias | D020447 | — | G47.5 | — | 1 | 2 | — | — | 3 |
| Dementia | D003704 | EFO_0003862 | F03 | — | — | 1 | — | — | 1 |
| Psychophysiologic disorders | D011602 | — | F45.9 | — | — | 1 | — | — | 1 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | 1 | — | — | 1 |
| Somatoform disorders | D013001 | — | F45 | — | — | 1 | — | — | 1 |
| Amyotrophic lateral sclerosis | D000690 | HP_0007354 | G12.21 | — | 1 | 1 | — | — | 1 |
| Motor neuron disease | D016472 | EFO_0003782 | G12.2 | — | 1 | 1 | — | — | 1 |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | — | — | 1 | — | — | 1 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.9 | — | — | 1 | — | — | 1 |
Show 1 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pain | D010146 | EFO_0003843 | R52 | — | 2 | — | — | 1 | 3 |
| Diabetic neuropathies | D003929 | EFO_1000783 | — | — | 2 | — | — | — | 2 |
| Hypokinesia | D018476 | — | — | 1 | 1 | — | — | — | 1 |
| Psychological sexual dysfunctions | D020018 | — | F52.0 | 1 | 1 | — | — | — | 1 |
| Respiratory aspiration | D053120 | EFO_1001839 | — | — | 1 | — | — | — | 1 |
| Alcoholism | D000437 | EFO_0003829 | F10.1 | — | 1 | — | — | — | 1 |
| Dyssomnias | D020920 | — | — | — | 1 | — | — | — | 1 |
| Amnesia | D000647 | EFO_1001454 | F44.0 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 7 | — | — | — | — | 7 |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | 4 | — | — | — | 1 | 5 |
| Traumatic stress disorders | D040921 | — | — | 3 | — | — | — | — | 3 |
| Brain injuries | D001930 | — | S06.9 | 1 | — | — | — | 1 | 2 |
| Postpartum depression | D019052 | EFO_0007453 | F53.0 | 2 | — | — | — | — | 2 |
| Traumatic brain injuries | D000070642 | — | S06 | 1 | — | — | — | — | 1 |
| Brain concussion | D001924 | — | S06.0 | 1 | — | — | — | — | 1 |
| Central sleep apnea | D020182 | — | G47.31 | 1 | — | — | — | — | 1 |
| Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
| Biological availability | D001682 | — | — | 1 | — | — | — | — | 1 |
Show 2 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pathologic constriction | D003251 | — | — | — | — | — | — | 1 | 1 |
| Spinal stenosis | D013130 | EFO_0007490 | M48.0 | — | — | — | — | 1 | 1 |
| Chronic disease | D002908 | — | — | — | — | — | — | 1 | 1 |
| Alcohol-related disorders | D019973 | — | F10 | — | — | — | — | 1 | 1 |
| Suicidal ideation | D059020 | EFO_0004320 | R45.851 | — | — | — | — | 1 | 1 |
| Hypotension | D007022 | EFO_0005251 | I95 | — | — | — | — | 1 | 1 |
| Orthostatic hypotension | D007024 | — | I95.1 | — | — | — | — | 1 | 1 |
| Problem behavior | D000066553 | — | — | — | — | — | — | 1 | 1 |
| Physiological sexual dysfunction | D012735 | — | — | — | — | — | — | 1 | 1 |
| Sepsis-associated encephalopathy | D065166 | — | G93.41 | — | — | — | — | 1 | 1 |
Show 3 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Trazodone |
| INN | trazodone |
| Description | Trazodone is an N-arylpiperazine in which one nitrogen is substituted by a 3-chlorophenyl group, while the other is substituted by a 3-(3-oxo[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)propyl group. It has a role as an antidepressant, a sedative, an adrenergic antagonist, a H1-receptor antagonist, a serotonin uptake inhibitor and an anxiolytic drug. It is a N-alkylpiperazine, a N-arylpiperazine, a triazolopyridine and a member of monochlorobenzenes. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=c1n(CCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12 |
Identifiers
| PDB | — |
| CAS-ID | 19794-93-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL621 |
| ChEBI ID | 9654 |
| PubChem CID | 5533 |
| DrugBank | DB00656 |
| UNII ID | YBK48BXK30 (ChemIDplus, GSRS) |
Target
Agency Approved
HTR2C
HTR2C
HTR2A
HTR2A
Organism
Homo sapiens
Gene name
HTR2C
Gene synonyms
HTR1C
NCBI Gene ID
Protein name
5-hydroxytryptamine receptor 2C
Protein synonyms
5-HT-1C, 5-HT1C, 5-hydroxytryptamine (serotonin) receptor 2C, G protein-coupled, 5-hydroxytryptamine receptor 1C, serotonin 5-HT-1C receptor, serotonin 5-HT-2C receptor, Serotonin receptor 2C
Uniprot ID
Mouse ortholog
Htr2c (15560)
5-hydroxytryptamine receptor 2C (Q5WRU6)
Alternate
HTR2B
HTR2B
Organism
Homo sapiens
Gene name
HTR2B
Gene synonyms
NCBI Gene ID
Protein name
5-hydroxytryptamine receptor 2B
Protein synonyms
5-HT 2B receptor, 5-hydroxytryptamine (serotonin) receptor 2B, G protein-coupled, 5-hydroxytryptamine 2B receptor, Serotonin receptor 2B
Uniprot ID
Mouse ortholog
Htr2b (15559)
5-hydroxytryptamine receptor 2B (Q9QWS2)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Trazodone
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 7,662 documents
View more details
Safety
Black-box Warning
Black-box warning for: Desyrel, Trazodone hcl, Trazodone hydrochloride
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
22,909 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use